Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop selling the “copycat” compounded versions it has long advertised. In a press release, Hims & Hers said it will “no longer advertise compounded GLP-1 offerings on…
